MRK | Weekly | Haru Insights

Merck (MRK) achieved a landmark Phase 3 trial success with Moderna’s personalized mRNA cancer vaccine, intismeran autogene, when combined with Keytruda, demonstrating a 49% reduction in recurrence or death in high-risk melanoma patients—meeting both primary and secondary endpoints.
The FDA accepted the sBLA for ENFLONSIA, and new KEYTRUDA combination approvals were granted in Canada, signaling strategic expansion beyond traditional oncology and reinforcing MRK’s growing role in next-generation immuno-oncology therapies.

MRK has decisively transformed into a leader in personalized cancer immunotherapy, with intismeran autogene’s proven superiority over Keytruda monotherapy marking a generational leap in oncology.
The company’s strategic pivot into AI-driven drug discovery via Evaxion A/S and EVX-B3 is positioning MRK as a tech-enabled innovator, not just a legacy drugmaker, with long-term disruptive potential.
Intismeran’s success in melanoma could catalyze a new standard of care across multiple cancers—lung, bladder, kidney—unlocking massive future revenue and re-rating MRK as a diversified biopharma powerhouse.
Despite a $1.3 billion GAAP loss in Q2 2026, MRK raised full-year guidance and delivered $16.6 billion in sales, proving its resilience and commitment to high-stakes innovation without compromising financial momentum.
The market’s 42% year-to-date rally and Morgan Stanley’s upgrade to Overweight reflect growing confidence in MRK’s ability to deliver transformative growth, validating its reinvention narrative.

Merck & Co., Inc. (MRK)[Tv]